Condition: Relapsed/Refractory Multiple Myeloma (RRMM) · Sponsor: Janssen-Cilag Ltd.
The purpose of this study is to describe the use of teclistamab/talquetamab in the treatment of patients with RRMM outside of clinical trials.
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| Aalborg Sygehus Syd | Aalborg, Denmark | Recruiting |
| Aarhus Universitetshospital | Aarhus N, Denmark | Completed |
| Rigshospitalet | Copenhagen, Denmark | Completed |
| Odense University Hospital | Odense, Denmark | Completed |
| Sygehus Lillebælt, Vejle | Vejle, Denmark | Recruiting |
| Hopital Albert Calmette - CHU Lille | Lille, France | Recruiting |
| Institut Paoli Calmettes | Marseille, France | Completed |
| CHU de Nantes hotel Dieu | Nantes, France | Recruiting |
| Hopital Saint Louis | Paris, France | Completed |
| Institut Universitaire du Cancer Toulouse Oncopole | Toulouse, France | Recruiting |
| CHRU de Nancy - Hopitaux de Brabois | Vandœuvre-lès-Nancy, France | Completed |
| Klinikum Chemnitz gGmbH | Chemnitz, Germany | Completed |
+ 56 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06285318